EGFR and neoplasm: Martinez-Marti et al. found that the combination of the MET inhibitor, capmatinib, and Erb-B2 receptor tyrosine kinases, ErbB-1/2/4, inhibitors successfully inhibited tumor growth in NSCLC-bearing mice [43].